An international team of scientists has identified an association between heritable, rare mutations in the RINT1 gene and increased risk of early onset breast cancer.
This is according to research reported (Oct. 24) at the American Society of Human Genetics 2013 annual meeting in Boston.
Value and Limitations of Patient Assistance Programs for Women With Breast Cancer Found
Patient assistance programs can help breast cancer patients meet a variety of needs that can interfere with getting recommended adjuvant therapies such as radiation, chemotherapy and hormonal treatments.
Advertisement
The rare mutations in RINT1, a tumor suppressor gene, were detected in three of 49 families participating in a study that sequenced the whole exome, the protein-coding DNA, of families with multiple individuals affected by breast cancer.
"Although mutations in RINT1 are rare, it is most likely that the remaining unknown breast cancer susceptibility genes will account for similar small proportions of the disease," said Daniel J Park, Ph.D., who presented the study at ASHG 2013 and is Senior Research Fellow in genetic epidemiology at the University of Melbourne, Australia.
![New Drug Proves Effective in Drug-resistant Breast Cancer and Melanoma]( "New Drug Proves Effective in Drug-resistant Breast Cancer and Melanoma")
LEE011 shows promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, say researchers.
Only about 35 percent of the familial risk for breast cancer has been explained, according to Dr. Park and his collaborators, who added that the discovery of the RINT1 variants' association with the disease could help members of families with multiple cases of breast cancer to identify their individual risk for developing the cancer.
Dr. Park's collaborators in the search for unidentified breast cancer susceptibility genes are scientists at the Institute Curie in Paris, International Agency for Research on Cancer in Lyon, France, Huntsman Cancer Institute in Salt Lake City, Utah, as well as the University of Melbourne.
After pinpointing the first three mutations in RINT1 (p.Q115X, p.M378del and p.D403Y), the international team of scientists assessed the association between the variants and breast cancer risk by conducting a population-based case-control study of 1,313 women diagnosed with early-onset breast cancer. Rare RINT1 variants were uncovered in 23 individuals in this group, but in only 6 women out of 1,123 who did not have breast cancer, demonstrating a significant association between RINT1 mutations and risk of early onset breast cancer, according to the researchers.
In parallel, an additional 684 women with breast cancer who are members of multiple-case breast cancer families were screened for RINT1 mutations, and six additional rare mutations were identified.
The scientists reported that research identifying RINT1 as a breast cancer susceptibility gene is consistent with prior studies showing that mice that carry a RINT1 mutation spontaneously develop a variety of tumors, including breast cancer, at a combined rate of 81 percent, which is higher than the rate at which breast cancer spontaneously develops in laboratory mice that have a BRCA1 mutation.
In their analysis of the families of women with RINT1 mutations, the researchers found a statistically significant 2 to 3-fold excess of cancers associated with mismatch repair defects, such as those found in patients with hereditary colorectal cancer without polyps. This finding indicates that RINT1 mutations may predispose to several other types of tumors, the scientists reported.
Previous studies have shown that RINT1 serves as a tumor suppressor essential for maintaining the function of the Golgi apparatus, which packages proteins inside the cell, and the integrity of the centrosome, which coordinates mitosis, a stage of cell division that separates two identical sets of chromosomes into newly dividing cells.
The scientists' ASHG abstract is titled: "Rare mutations in RINT1 predispose carriers to early-onset breast cancer."
Source: Eurekalert
New Drug Proves Effective in Drug-resistant Breast Cancer and Melanoma
LEE011 shows promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, say researchers.
Advertisement
Only about 35 percent of the familial risk for breast cancer has been explained, according to Dr. Park and his collaborators, who added that the discovery of the RINT1 variants' association with the disease could help members of families with multiple cases of breast cancer to identify their individual risk for developing the cancer.
Dr. Park's collaborators in the search for unidentified breast cancer susceptibility genes are scientists at the Institute Curie in Paris, International Agency for Research on Cancer in Lyon, France, Huntsman Cancer Institute in Salt Lake City, Utah, as well as the University of Melbourne.
After pinpointing the first three mutations in RINT1 (p.Q115X, p.M378del and p.D403Y), the international team of scientists assessed the association between the variants and breast cancer risk by conducting a population-based case-control study of 1,313 women diagnosed with early-onset breast cancer. Rare RINT1 variants were uncovered in 23 individuals in this group, but in only 6 women out of 1,123 who did not have breast cancer, demonstrating a significant association between RINT1 mutations and risk of early onset breast cancer, according to the researchers.
In parallel, an additional 684 women with breast cancer who are members of multiple-case breast cancer families were screened for RINT1 mutations, and six additional rare mutations were identified.
The scientists reported that research identifying RINT1 as a breast cancer susceptibility gene is consistent with prior studies showing that mice that carry a RINT1 mutation spontaneously develop a variety of tumors, including breast cancer, at a combined rate of 81 percent, which is higher than the rate at which breast cancer spontaneously develops in laboratory mice that have a BRCA1 mutation.
In their analysis of the families of women with RINT1 mutations, the researchers found a statistically significant 2 to 3-fold excess of cancers associated with mismatch repair defects, such as those found in patients with hereditary colorectal cancer without polyps. This finding indicates that RINT1 mutations may predispose to several other types of tumors, the scientists reported.
Previous studies have shown that RINT1 serves as a tumor suppressor essential for maintaining the function of the Golgi apparatus, which packages proteins inside the cell, and the integrity of the centrosome, which coordinates mitosis, a stage of cell division that separates two identical sets of chromosomes into newly dividing cells.
The scientists' ASHG abstract is titled: "Rare mutations in RINT1 predispose carriers to early-onset breast cancer."
Source: Eurekalert
Different Anesthesia Techniques May Reduce Breast Cancer Recurrence
Breast cancer patients who received the combination of a nerve block with general anesthesia for their breast cancer surgery had less cancer recurrence and were three times less likely to die than those who received only general anesthesia.
Advertisement
Scientists Discover Potential New Treatment for Triple-negative Breast Cancer
A novel method to treat 'triple-negative' breast cancer has been identified by scientists.
Advertisement
Recommended Reading
Latest Research News
The International Space Station will be used to carry out experiments seeking to improve understanding of incurable child brain tumors and the muscle aging process.
How many people in the UK have misophonia? In a representative sample study, most people had at least some irritation upon hearing trigger sounds.
Routine eye-checkups and mass screenings enable early diagnosis and treatment of glaucoma. Late-stage glaucoma diagnosis leads to blindness.
Brain plasticity following blindness leads to superior ability in sensing signals from the heart, which has implications for bodily awareness and emotional processing.
A group of scientists were awarded £1.3 million to create a new “point of care testing” kit that detects Alzheimer's disease biomarkers.
